Evidence map›Paper›PMID 35396829›Full record

ArticleJournal of diabetes investigation2022

Novel method utilizing bisulfite conversion with dual amplification-refractory mutation system polymerase chain reaction to detect circulating pancreatic β-cell cfDNA.

Asami Okada, Misuzu Yamada-Yamashita, Yukari Tominaga, Kyoka Jo, Hiroyasu Mori, Reiko Suzuki, Masashi Ishizu, Motoyuki Tamaki, Yuko Akehi, Yuichi Takashi and 15 more

Open access · goldAbstract read
In one paragraph

Article in Journal of diabetes investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 6 institutions in 2 countries.

Asami Okada *Department of Pediatrics, Tokushima University, Tokushima, Japan.
Misuzu Yamada-Yamashita *Diabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.
Yukari TominagaDiabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.
Kyoka JoDiabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.
Hiroyasu MoriDiabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.
Reiko SuzukiDiabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.
Masashi IshizuDiabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.
Motoyuki TamakiDiabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.
Yuko AkehiDiabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.
Yuichi TakashiDiabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.ORCID https://orcid.org/0000-0002-3728-1139
Daisuke KogaDiagnostic Division, Department of Research, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.
Eisuke ShimokitaDepartment of Anatomy and Cell Biology, Tokushima University Graduate School of Medical Sciences, Tokushima, Japan.
Fuminori TaniharaAnimal Resource Laboratory, Center for Development of Advanced Medical Technology, Jichi Medical University, Shimotsuke, Japan.
Kiyoe KurahashiDepartment of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Sumiko YoshidaDepartment of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Yukari MitsuiDepartment of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Shiho MasudaDepartment of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Itsuro EndoDepartment of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Ken-Ichi AiharaDepartment of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.ORCID https://orcid.org/0000-0001-8906-0920
Shoji KagamiDepartment of Pediatrics, Tokushima University, Tokushima, Japan.
Masahiro AbeDepartment of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Kevin FerreriDepartment of Translational Research & Cellular Therapeutics, City of Hope, Duarte, California, USA.
Yoshio FujitaniDevelopmental Biology and Metabolism, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan.ORCID https://orcid.org/0000-0003-0196-4736
Munehide MatsuhisaDiabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.ORCID https://orcid.org/0000-0003-4624-939X
Akio KurodaDiabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.ORCID https://orcid.org/0000-0003-2147-6844
Tokushima University Hospital · JPTokushima University · JPCity of Hope · USGunma University · JPJichi Medical University · JPOtsuka (Japan) · JP

Funding

Grant-in-Aid for Scientific Research 15K06910Grant-in-Aid for Scientific Research 18K07448The joint research program of the Institute for Molecular and Cellular Regulation, Gunma University 18020
6 · The paper itself

Abstract

AIMS/

introductionSeveral research groups have reported methods for quantifying pancreatic beta cell (β-cell) injury by measuring β-cell-specific CpG unmethylation of the insulin gene in circulation using digital droplet PCR or next-generation sequencing. However, these methods have certain disadvantages, such as the need to consider the background signal owing to the small number of target CpG sites and the need for unique equipment. MATERIALS AND

methodsWe established a novel method for detecting four CpG unmethylations of the insulin gene using two-step amplification refractory mutation system PCR. We applied it to type 1 diabetes (T1D) patients with a wide range of disease durations and to healthy adults.

resultsThe assay showed high linearity and could detect a single copy of unmethylated insulin DNA in experiments using methylated and unmethylated plasmid DNA. The unmethylated insulin DNA level in the type 1 diabetes group, whose β-cell mass was considerably reduced, was similar to that of healthy adults. An inverse correlation was observed between copy number and disease duration in patients with unmethylated insulin DNA-positive type 1 diabetes.

conclusionsWe developed a novel method for detecting unmethylated insulin DNA in circulation that can be performed using a conventional real-time PCR system. This method would be useful for analyzing dynamic profiles of β-cells in human disease such as type 1 diabetes.

Indexed as

Cell-Free Nucleic AcidsDiabetes Mellitus, Type 1Insulin-Secreting CellsAdultDNADNA MethylationHumansInsulinMutationReal-Time Polymerase Chain ReactionSulfitesCell-Free Nucleic AcidsDNAhydrogen sulfiteInsulinSulfitesDNA methylationQuantitative RT-PCRType 1 diabetes

Identifiers

PMID35396829
PMCPMC9248415
OpenAlexW4223431869

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.